Regeneron Pharmaceutical (REGN) 410.39 $REGN Re
Post# of 273327
Posted On: 09/24/2016 5:09:51 PM
Regeneron Pharmaceutical (REGN) 410.39 $REGN
Regeneron, Teva Collaborate to Develop Chronic Pain Drug
Zacks Equity Research - Zacks Investment Research - Wed Sep 21, 2:08PM CDT
Regeneron (REGN) and Teva have inked a deal for the development and commercialization of experimental NGF antibody, fasinumab, for chronic pain.
ANIP: 66.64 (-0.17), TEVA: 51.47 (+0.24), ANIK: 46.92 (-1.07), REGN: 410.39 (+2.38)
Regeneron Pharmaceuticals Falls 1.78% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Sep 21, 12:50PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $398.58 to a high of $410.39. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $400.23 on volume of 277,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
REGN: 410.39 (+2.38)
Biotech Stock Roundup: Tobira Soars on Acquisition Deal, FDA Says Yes to Sarepta DMD Drug
Arpita Dutt - Zacks Investment Research - Wed Sep 21, 7:39AM CDT
The biotech sector got a boost with Allergan announcing its intention to acquire Tobira as well as a couple of other companies.
BIIB: 312.58 (-2.23), VRTX: 90.63 (-1.49), GERN: 2.20 (-0.02), SRPT: 57.83 (-3.14), TBRA: 39.11 (-0.39), ALKS: 49.58 (-1.42), REGN: 410.39 (+2.38)
Teva and Regeneron Announce Global Collaboration to Develop and Commercialize Fasinumab, an Investigational NGF Antibody for Chronic Pain
BusinessWire - Tue Sep 20, 6:00AM CDT
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today a global(1) agreement to develop and commercialize fasinumab, Regeneron's investigational NGF antibody in Phase 3 clinical development for osteoarthritis pain and in Phase 2 development for chronic low back pain. Under the terms of the agreement, Teva will pay Regeneron $250 million upfront and share equally in the global(1) commercial value, as well as ongoing research and development costs of approximately $1 billion.
TEVA: 51.47 (+0.24), REGN: 410.39 (+2.38)
Regeneron and Teva Announce Global Collaboration to Develop and Commercialize Fasinumab, an Investigational NGF Antibody for Chronic Pain
PR Newswire - Tue Sep 20, 6:00AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today a global1 agreement to develop and commercialize fasinumab, Regeneron's investigational NGF antibody in Phase 3 clinical development for osteoarthritis pain and in Phase 2 development for chronic low back pain. Under the terms of the agreement, Teva will pay Regeneron $250 million upfront and share equally in the global1 commercial value, as well as ongoing research and development costs of approximately $1 billion.
TEVA: 51.47 (+0.24), REGN: 410.39 (+2.38)
Watch for Regeneron Pharmaceuticals to Potentially Pullback After Gaining 1.46% Yesterday
Comtex SmarTrend(R) - Wed Sep 14, 12:42PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $391.70 to a high of $401.80. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $399.83 on volume of 326,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
REGN: 410.39 (+2.38)
Regeneron Announces Election of Bonnie Bassler, Ph.D., and Huda Zoghbi, M.D., to Board of Directors
PR Newswire - Mon Sep 12, 7:30AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the appointment of noted scientists Bonnie L. Bassler, Ph.D., and Huda Y. Zoghbi, M.D., to the company's Board of Directors.
REGN: 410.39 (+2.38)
Look for Shares of Regeneron Pharmaceuticals to Potentially Pullback after Yesterday's 2.82% Rise
Comtex SmarTrend(R) - Tue Sep 06, 1:50PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $390.15 to a high of $401.40. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $397.27 on volume of 471,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
REGN: 410.39 (+2.38)
After Yesterday's Decline of 1.30%, Regeneron Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Fri Sep 02, 12:49PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $387.77 to a high of $393.97. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $390.02 on volume of 318,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
REGN: 410.39 (+2.38)
Biotech Stock Roundup: Gilead in Patent Infringement Lawsuit, Enbrel Biosimilar Approved
Arpita Dutt - Zacks Investment Research - Thu Sep 01, 9:54AM CDT
The overall healthcare sector was under pressure with focus going back to the pricing policies of pharma and biotech companies.
GILD: 81.37 (-0.15), ALXN: 127.22 (-6.47), MYL: 42.06 (-0.53), AMGN: 174.80 (-0.82), ARIA: 13.52 (-0.11), RIGL: 3.44 (-0.01), REGN: 410.39 (+2.38)
Regeneron Announces Upcoming 2016 Investor Conference Presentations
PR Newswire - Thu Sep 01, 8:30AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast a management presentation at the following investor conferences:
REGN: 410.39 (+2.38)
The Medicines Co. Offers Update on Dyslipidemia Programs
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 9:13AM CDT
The Medicines Company (MDCO) provided an update on its dyslipidemia programs - MDCO-216 and PCSK9si (PCSK9 synthesis inhibitor).
MDCO: 40.45 (-1.05), AMGN: 174.80 (-0.82), SNY: 38.35 (-0.22), REGN: 410.39 (+2.38)
Regeneron/Sanofi Present Positive Phase III Praluent Data
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 8:33AM CDT
Regeneron Pharmaceuticals (REGN) and Sanofi presented positive phase III data on Praluent in patients who underwent LDL apheresis therapy.
ANIP: 66.64 (-0.17), AMGN: 174.80 (-0.82), SNY: 38.35 (-0.22), REGN: 410.39 (+2.38)
Regeneron and Sanofi Present Positive Phase 3 Investigational Data for Praluent® (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016
PR Newswire - Mon Aug 29, 1:00AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced detailed positive results from ODYSSEY ESCAPE, a Phase 3 trial which evaluated Praluent® (alirocumab) Injection in patients with an inherited form of high cholesterol known as heterozygous familial hypercholesterolemia (HeFH) who require regular weekly or bi-weekly apheresis treatment. The trial demonstrated that adding Praluent to existing therapy reduced LDL cholesterol by approximately 50 percent from baseline (compared to 2 percent increase for placebo). Praluent significantly reduced the need for apheresis treatment by 75 percent compared to placebo (p less than 0.0001), the primary endpoint of the study. Results will be presented today at a Hot Line session at the ESC Congress 2016 in Rome, Italy.
SAN: 4.43 (-0.14), SNY: 38.35 (-0.22), REGN: 410.39 (+2.38)
Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review
Arpita Dutt - Zacks Investment Research - Wed Aug 24, 1:09PM CDT
Acquisitions are back in focus in the biotech sector with Medivation (MDVN) agreeing to be acquired by Pfizer for $14 billion.
MDVN: 81.42 (+0.34), BIIB: 312.58 (-2.23), PTLA: 23.20 (-0.52), CLVS: 37.14 (-1.22), GILD: 81.37 (-0.15), ALXN: 127.22 (-6.47), REGN: 410.39 (+2.38)
Regeneron Stock Up on BARDA Deal for MERS Antibodies
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 8:48AM CDT
Regeneron Pharmaceuticals (REGN) has signed up with BARDA for the development of treatments targeting MERS viru
ANIP: 66.64 (-0.17), GERN: 2.20 (-0.02), SNY: 38.35 (-0.22), REGN: 410.39 (+2.38)
Medivation and Syngenta climb; Viacom, Marathon Oil fall
AP - Mon Aug 22, 3:43PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Monday:
MDVN: 81.42 (+0.34), VIA: 39.74 (-0.45), MUR: 26.08 (-1.47), SYT: 88.15 (+0.42), PFE: 34.26 (+0.11), ODP: 3.71 (+0.08), MRO: 14.49 (-0.38), ISIL: 21.85 (-0.05), VIAB: 35.50 (-0.32), REGN: 410.39 (+2.38)
After Yesterday's Rally of 4.34% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Aug 22, 12:10PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $405.10 to a high of $422.30. Yesterday, the shares gained 4.3%, which took the trading range above the 3-day high of $415.82 on volume of 508,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
REGN: 410.39 (+2.38)
Regeneron, Teva Collaborate to Develop Chronic Pain Drug
Zacks Equity Research - Zacks Investment Research - Wed Sep 21, 2:08PM CDT
Regeneron (REGN) and Teva have inked a deal for the development and commercialization of experimental NGF antibody, fasinumab, for chronic pain.
ANIP: 66.64 (-0.17), TEVA: 51.47 (+0.24), ANIK: 46.92 (-1.07), REGN: 410.39 (+2.38)
Regeneron Pharmaceuticals Falls 1.78% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Sep 21, 12:50PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $398.58 to a high of $410.39. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $400.23 on volume of 277,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
REGN: 410.39 (+2.38)
Biotech Stock Roundup: Tobira Soars on Acquisition Deal, FDA Says Yes to Sarepta DMD Drug
Arpita Dutt - Zacks Investment Research - Wed Sep 21, 7:39AM CDT
The biotech sector got a boost with Allergan announcing its intention to acquire Tobira as well as a couple of other companies.
BIIB: 312.58 (-2.23), VRTX: 90.63 (-1.49), GERN: 2.20 (-0.02), SRPT: 57.83 (-3.14), TBRA: 39.11 (-0.39), ALKS: 49.58 (-1.42), REGN: 410.39 (+2.38)
Teva and Regeneron Announce Global Collaboration to Develop and Commercialize Fasinumab, an Investigational NGF Antibody for Chronic Pain
BusinessWire - Tue Sep 20, 6:00AM CDT
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today a global(1) agreement to develop and commercialize fasinumab, Regeneron's investigational NGF antibody in Phase 3 clinical development for osteoarthritis pain and in Phase 2 development for chronic low back pain. Under the terms of the agreement, Teva will pay Regeneron $250 million upfront and share equally in the global(1) commercial value, as well as ongoing research and development costs of approximately $1 billion.
TEVA: 51.47 (+0.24), REGN: 410.39 (+2.38)
Regeneron and Teva Announce Global Collaboration to Develop and Commercialize Fasinumab, an Investigational NGF Antibody for Chronic Pain
PR Newswire - Tue Sep 20, 6:00AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today a global1 agreement to develop and commercialize fasinumab, Regeneron's investigational NGF antibody in Phase 3 clinical development for osteoarthritis pain and in Phase 2 development for chronic low back pain. Under the terms of the agreement, Teva will pay Regeneron $250 million upfront and share equally in the global1 commercial value, as well as ongoing research and development costs of approximately $1 billion.
TEVA: 51.47 (+0.24), REGN: 410.39 (+2.38)
Watch for Regeneron Pharmaceuticals to Potentially Pullback After Gaining 1.46% Yesterday
Comtex SmarTrend(R) - Wed Sep 14, 12:42PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $391.70 to a high of $401.80. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $399.83 on volume of 326,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
REGN: 410.39 (+2.38)
Regeneron Announces Election of Bonnie Bassler, Ph.D., and Huda Zoghbi, M.D., to Board of Directors
PR Newswire - Mon Sep 12, 7:30AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the appointment of noted scientists Bonnie L. Bassler, Ph.D., and Huda Y. Zoghbi, M.D., to the company's Board of Directors.
REGN: 410.39 (+2.38)
Look for Shares of Regeneron Pharmaceuticals to Potentially Pullback after Yesterday's 2.82% Rise
Comtex SmarTrend(R) - Tue Sep 06, 1:50PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $390.15 to a high of $401.40. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $397.27 on volume of 471,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
REGN: 410.39 (+2.38)
After Yesterday's Decline of 1.30%, Regeneron Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Fri Sep 02, 12:49PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $387.77 to a high of $393.97. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $390.02 on volume of 318,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
REGN: 410.39 (+2.38)
Biotech Stock Roundup: Gilead in Patent Infringement Lawsuit, Enbrel Biosimilar Approved
Arpita Dutt - Zacks Investment Research - Thu Sep 01, 9:54AM CDT
The overall healthcare sector was under pressure with focus going back to the pricing policies of pharma and biotech companies.
GILD: 81.37 (-0.15), ALXN: 127.22 (-6.47), MYL: 42.06 (-0.53), AMGN: 174.80 (-0.82), ARIA: 13.52 (-0.11), RIGL: 3.44 (-0.01), REGN: 410.39 (+2.38)
Regeneron Announces Upcoming 2016 Investor Conference Presentations
PR Newswire - Thu Sep 01, 8:30AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast a management presentation at the following investor conferences:
REGN: 410.39 (+2.38)
The Medicines Co. Offers Update on Dyslipidemia Programs
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 9:13AM CDT
The Medicines Company (MDCO) provided an update on its dyslipidemia programs - MDCO-216 and PCSK9si (PCSK9 synthesis inhibitor).
MDCO: 40.45 (-1.05), AMGN: 174.80 (-0.82), SNY: 38.35 (-0.22), REGN: 410.39 (+2.38)
Regeneron/Sanofi Present Positive Phase III Praluent Data
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 8:33AM CDT
Regeneron Pharmaceuticals (REGN) and Sanofi presented positive phase III data on Praluent in patients who underwent LDL apheresis therapy.
ANIP: 66.64 (-0.17), AMGN: 174.80 (-0.82), SNY: 38.35 (-0.22), REGN: 410.39 (+2.38)
Regeneron and Sanofi Present Positive Phase 3 Investigational Data for Praluent® (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016
PR Newswire - Mon Aug 29, 1:00AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced detailed positive results from ODYSSEY ESCAPE, a Phase 3 trial which evaluated Praluent® (alirocumab) Injection in patients with an inherited form of high cholesterol known as heterozygous familial hypercholesterolemia (HeFH) who require regular weekly or bi-weekly apheresis treatment. The trial demonstrated that adding Praluent to existing therapy reduced LDL cholesterol by approximately 50 percent from baseline (compared to 2 percent increase for placebo). Praluent significantly reduced the need for apheresis treatment by 75 percent compared to placebo (p less than 0.0001), the primary endpoint of the study. Results will be presented today at a Hot Line session at the ESC Congress 2016 in Rome, Italy.
SAN: 4.43 (-0.14), SNY: 38.35 (-0.22), REGN: 410.39 (+2.38)
Biotech Stock Roundup: Medivation to Pfizer, Clovis Priority Review
Arpita Dutt - Zacks Investment Research - Wed Aug 24, 1:09PM CDT
Acquisitions are back in focus in the biotech sector with Medivation (MDVN) agreeing to be acquired by Pfizer for $14 billion.
MDVN: 81.42 (+0.34), BIIB: 312.58 (-2.23), PTLA: 23.20 (-0.52), CLVS: 37.14 (-1.22), GILD: 81.37 (-0.15), ALXN: 127.22 (-6.47), REGN: 410.39 (+2.38)
Regeneron Stock Up on BARDA Deal for MERS Antibodies
Zacks Equity Research - Zacks Investment Research - Tue Aug 23, 8:48AM CDT
Regeneron Pharmaceuticals (REGN) has signed up with BARDA for the development of treatments targeting MERS viru
ANIP: 66.64 (-0.17), GERN: 2.20 (-0.02), SNY: 38.35 (-0.22), REGN: 410.39 (+2.38)
Medivation and Syngenta climb; Viacom, Marathon Oil fall
AP - Mon Aug 22, 3:43PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Monday:
MDVN: 81.42 (+0.34), VIA: 39.74 (-0.45), MUR: 26.08 (-1.47), SYT: 88.15 (+0.42), PFE: 34.26 (+0.11), ODP: 3.71 (+0.08), MRO: 14.49 (-0.38), ISIL: 21.85 (-0.05), VIAB: 35.50 (-0.32), REGN: 410.39 (+2.38)
After Yesterday's Rally of 4.34% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Aug 22, 12:10PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $405.10 to a high of $422.30. Yesterday, the shares gained 4.3%, which took the trading range above the 3-day high of $415.82 on volume of 508,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
REGN: 410.39 (+2.38)
(0)
(0)